Table 1 Demographic data
From: Daily vancomycin dose requirements as a continuous infusion in obese versus non-obese SICU patients
Obese patients (n = 26) | Non obese patients (n = 26) | P value | |
|---|---|---|---|
Age, years | 54.2 (16.8) | 55.4 (16.0) | 0.781 |
Male, n | 18 | 21 | 0.337 |
TBW, kg | 117 (23.3) | 75.2 (13.3) | <0.001 |
ABW, kg | 87.7 (13.7) | 71.0 (11.1) | <0.001 |
IBW, kg | 67.9 (13.1) | 68.5 (10.5) | 0.88 |
Height, in | 67.6 (4.63) | 68.5 (3.38) | 0.393 |
Over IBW, % | 1.77 (0.43) | 1.1 (0.112) | <0.001 |
BMI, kg/m2 | 41.0 (8.12) | 24.9 (3.16) | <0.001 |
APACHE II | 20.3 (9.24) | 18.7 (8.46) | 0.524 |
Hospital mortality, n | 5 | 4 | 0.714 |
Mechanical ventilation, n | 24 | 26 | 0.149 |
Use of vasopressors, n | 15 | 20 | 0.139 |
CVVH, n | 9 | 9 | 1 |
Urine creatinine clearance (ml/min), n = 17 | 166 (62.7) | 168.1 (59.1) | 0.92 |
CVVH flow rate, ml/kg/h | 21.3 (7.09) | 21.9 (6.47) | 0.86 |
Duration of vancomycin, days | 6.88 (3.02) | 6.5 (3.06) | 0.415 |
Time from ICU admission to vancomycin initiation, days | 2.73 (1.66) | 2.53 (1.33) | 0.647 |
Infection site - Pneumonia - Bacteremia - SSTI - Intraabdominal - Unknown | 16 2 2 3 3 | 19 0 3 2 2 | 0.375 0.149 0.638 0.638 0.638 |
Microbiology results - MRSA - MSSA - Enterococcus - Streptococcus spp. - CoN Staphylococcus - Other | 6 2 0 2 4 12 | 7 3 1 3 3 9 | 0.749 0.638 0.313 0.638 0.685 0.397 |